Recombinant human Interleukin-7 (r-hIL-7) is a critical growth factor for immune T-cell recovery and enhancement.
Laureate claims that clinical investigations conducted on more than 75 patients in Europe, the US and Canada have suggested the potential of r-hIL-7 to expand and protect CD4+ and CD8+ T-cells.
Robert Broeze, president and CEO of Laureate, said: “We are delighted that Cytheris has selected us again as their contract manufacturing organization, to manufacture IL-7 in support of their expanded clinical trial program.
“This is a testimonial to our successful partnership with our clients and our effort to achieve their total satisfaction in our ability to meet their manufacturing needs. We will work with the Cytheris team very closely and help them realize the greatest potential of their IL-7 development and production program.”